PMID- 35790062
OWN - NLM
STAT- MEDLINE
DCOM- 20220908
LR  - 20221205
IS  - 1529-8019 (Electronic)
IS  - 1396-0296 (Print)
IS  - 1396-0296 (Linking)
VI  - 35
IP  - 9
DP  - 2022 Sep
TI  - Infliximab in hidradenitis suppurativa: A systematic review and meta-analysis.
PG  - e15691
LID - 10.1111/dth.15691 [doi]
LID - e15691
AB  - Hidradenitis suppurativa (HS) is a chronic inflammatory often recalcitrant to 
      treatment. There is a lack of an updated systematic data review for infliximab 
      use in HS. We conducted a systematic review and meta-analysis of literature on 
      infliximab in HS. This study was performed following Preferred Reporting Items 
      for Systematic Reviews and Meta-Analyses guidelines and was pre-registered on 
      PROSPERO (CRD42021283596). In 9/2021, MEDLINE and EMBASE were systematically 
      searched for articles on infliximab in HS. Non-English, duplicate, and studies 
      with <5 HS patients were excluded. Study quality was assessed utilizing Cochrane 
      Risk of Bias for prospective trials and Newcastle-Ottawa Scale for cohort 
      studies. Random effects meta-analytical model, Cochran's Q statistic, and I 
      squared index were performed. Nineteen articles (314 patients) met inclusion 
      criteria (six prospective, 13 retrospective studies). All patients with HS 
      severity data available (n = 299) had moderate-to-severe disease. Outcome 
      measures used for meta-analysis of the pooled response rate were largely based on 
      clinician reported outcomes (16 studies). One utilized both clinician and patient 
      assessment. Two utilized patient-reported response alone. The pooled response 
      rate of HS patients to infliximab was 83% (95% CI, 0.71-0.91). The most common 
      adverse events (AEs) included non-serious infections (13.2%) and infusion 
      reaction (2.9%). The rate of serious AEs was 2.9%. Study limitations include the 
      small number of prospective studies and heterogeneity between studies. Overall, 
      infliximab is an effective treatment for moderate-to-severe HS. Efficacy of 
      infliximab in HS should be compared to other biologics in larger, randomized 
      controlled trials.
CI  - (c) 2022 The Authors. Dermatologic Therapy published by Wiley Periodicals LLC.
FAU - Shih, Terri
AU  - Shih T
AD  - David Geffen School of Medicine, University of California Los Angeles, Los 
      Angeles, California, USA.
FAU - Lee, Katrina
AU  - Lee K
AD  - Department of Dermatology, University of California Los Angeles, Los Angeles, 
      California, USA.
FAU - Grogan, Tristan
AU  - Grogan T
AD  - Department of Medicine Statistics Core, David Geffen School of Medicine, 
      University of California, Los Angeles, California, USA.
FAU - De, Devea R
AU  - De DR
AD  - Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, 
      Buffalo, New York, USA.
FAU - Shi, Vivian Y
AU  - Shi VY
AUID- ORCID: 0000-0002-7510-9428
AD  - Department of Dermatology, University of Arkansas for Medical Sciences, Little 
      Rock, Arkansas, USA.
FAU - Hsiao, Jennifer L
AU  - Hsiao JL
AUID- ORCID: 0000-0002-8843-3630
AD  - Department of Dermatology, University of Southern California, Los Angeles, 
      California, USA.
LA  - eng
GR  - UL1TR001881/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20220718
PL  - United States
TA  - Dermatol Ther
JT  - Dermatologic therapy
JID - 9700070
RN  - 0 (Antibodies, Monoclonal)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Antibodies, Monoclonal/adverse effects
MH  - *Hidradenitis Suppurativa/chemically induced/drug therapy
MH  - Humans
MH  - Infliximab/adverse effects
MH  - Prospective Studies
MH  - Retrospective Studies
PMC - PMC9539481
OTO - NOTNLM
OT  - hidradenitis suppurativa
OT  - infliximab
OT  - meta-analysis
COIS- JLH is on the Board of Directors for the Hidradenitis Suppurativa Foundation, has 
      served as a consultant for Boehringer Ingelheim, Novartis, and UCB, and has 
      served as a consultant and speaker for AbbVie. VYS is on the board of directors 
      for the Hidradenitis Suppurativa Foundation (HSF), is a stock shareholder of 
      Learn Health and has served as an advisory board member, investigator, speaker, 
      and/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Eli 
      Lilly, Novartis, SUN Pharma, LEO Pharma, Pfizer, Incyte, Boehringer-Ingelheim, 
      Aristea Therapeutics, Menlo Therapeutics, Dermira, Burt's Bees, Galderma, 
      Kiniksa, UCB, WebMD, TARGET-Pharmasolutions, Altus Lab, MYOR, Polyfin, GpSkin and 
      Skin Actives Scientific. There was no financial transaction for the preparation 
      of this manuscript. All other authors report no conflicts of interest.
EDAT- 2022/07/06 06:00
MHDA- 2022/09/09 06:00
PMCR- 2022/10/07
CRDT- 2022/07/05 20:12
PHST- 2022/06/16 00:00 [revised]
PHST- 2022/04/07 00:00 [received]
PHST- 2022/07/01 00:00 [accepted]
PHST- 2022/07/06 06:00 [pubmed]
PHST- 2022/09/09 06:00 [medline]
PHST- 2022/07/05 20:12 [entrez]
PHST- 2022/10/07 00:00 [pmc-release]
AID - DTH15691 [pii]
AID - 10.1111/dth.15691 [doi]
PST - ppublish
SO  - Dermatol Ther. 2022 Sep;35(9):e15691. doi: 10.1111/dth.15691. Epub 2022 Jul 18.